Predicting rectal cancer treatment response using multi-omics
Part of Cancer clinical trials.
This trial is testing a new way to predict how well your rectal cancer will respond to treatments given before surgery. It uses advanced tests (like looking at genes and other markers) to tailor your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rectal adenocarcinoma (a type of rectal cancer that starts in the gland cells of the rectum).
- Your tumor should be at a stage where it has grown into or through the muscle layer of the rectum (T3 or T4), but not spread to distant organs.
- You cannot have had any previous chemotherapy, radiation, or immunotherapy for this cancer.
- You must not have serious heart problems, such as a recent heart attack or heart failure.
- You should not have active infections like tuberculosis, hepatitis B or C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special imaging analysis can predict where your cancer might spread. It's for people with advanced lung, colorectal, or breast cancer who are starting or continuing treatment.
This trial uses a special type of MRI scan (called amide proton transfer-weighted imaging) to look at your rectal cancer before and after chemotherapy and/or radiation. The goal is to see if the scan can predict whether the cancer has completely disappeared by the time of surgery, which could help guide future treatment decisions.
This study uses special MRI scans taken before and during immunotherapy to see if the cancer is truly growing or just appearing to grow, which is called 'pseudoprogression'. It helps doctors better understand how well the treatment is working for rectal cancer.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
This study uses metabolomics (analysis of small molecules in your body) to predict how well your rectal cancer will respond to treatment and whether you may experience side effects. It focuses on patients receiving total neoadjuvant therapy (treatment before surgery).
Hear when a new Predictive Cancer Model trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.